France Glucagon Delivery Device Market Size & Outlook, 2026-2034
France Glucagon Delivery Device Market Insights
- According to Reed Intelligence analysis, the France Glucagon Delivery Device Market size was USD 49.63 Million in 2025 and is projected to reach USD 114.07 Million by 2034.
- The France market is projected to grow at a CAGR of 9.75% between 2026 and 2034.
- By segment, Autoinjectors emerged as the largest Product Type in terms of market size in 2025.
- Nasal Devices is anticipated to remain the most attractive Product Type segment, recording the fastest growth during the forecast period.
![France Glucagon Delivery Device Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/france-glucagon-delivery-device-market-france-product-type-100438.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- France contributed 4.32% to the global Glucagon Delivery Device Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Glucagon Delivery Device Market.
- In Europe, Germany is projected to capture the leading share of market size by 2034.
- Among Europe markets, Russia is expected to post the fastest growth, reaching USD 69.53 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 49.63 Million |
| Market Size In 2034 | USD 114.07 Million |
| Largest segment | Autoinjectors |
| Units | Revenue in USD Million |
| CAGR | 9.75% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Glucagon Delivery Device Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Autoinjectors | XX.x | XX.x | XX.x | 22.37 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prefilled Syringes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nasal Devices | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Glucagon Delivery Device Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe Hypoglycemia | XX.x | XX.x | XX.x | 27.31 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Exercise-Induced Hypoglycemia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Glucagon Delivery Device Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 23.3 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Homecare Settings | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
